Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United ...
Wells Fargo maintained its 'Equal-Weight' rating on Centene (CNC) and raised its price target to $69.00, an increase of 23.21%. GuruFocus data suggests CNC is undervalued by 18.0% with a GF Value™ of $83.37, despite insider sales totaling $5.2 million over the past three months. The company's GF Score™ is 73/100, highlighting strong profitability and valuation but weaker growth.
BioMarin has announced that the FDA accepted its supplemental New Drug Application (sNDA) for VOXZOGO, targeting full approval for achondroplasia by February 28, 2027. This application is supported by extensive long-term safety and efficacy data from three ongoing studies, demonstrating significant improvements in skeletal growth for children. Full approval is expected to expand VOXZOGO's market reach, addressing global demand and enhancing BioMarin's revenue potential while solidifying its leadership in rare disease treatments.
Centene Corp. (ISIN US15133V1035) is a major US managed-care company focused on government-sponsored health plans like Medicaid and Medicare. The company's performance is heavily influenced by US healthcare policy, regulatory changes, and reimbursement trends, making these factors central to its long-term investment narrative. Centene's business model involves administering health benefits for various populations, with its success tied to effective medical cost management, disciplined underwriting, and strategic operational diversification.
Centene Corporation's subsidiary, Meridian Health Plan of Illinois, has secured a four-year renewal of its contract under the state's HealthChoice Illinois Medicaid program, effective from January 1, 2027, through 2030. This renewal, while not expected to significantly boost near-term earnings, is critical for maintaining premium revenues and enhancing long-term earnings visibility for Centene, given its reliance on government-sponsored healthcare programs. The company's shares have rallied 64.3% year-to-date, outperforming the industry, and its 2026 earnings are projected to grow by 66.4%.
Centene Corporation announced it will release its Q2FY26 financial results on Tuesday, July 28, 2026, at approximately 6:00 a.m. ET, followed by a conference call at 8:30 a.m. ET to discuss the results. Investors and interested parties can access the call via dial-in numbers or a live audio webcast through the company's website. Centene, a Fortune 500 healthcare enterprise, provides services to Medicaid, Medicare, and Health Insurance Marketplace members.
Wells Fargo maintained its 'Equal-Weight' rating on Centene (CNC) and raised its price target to $69.00, an increase of 23.21%. GuruFocus data suggests CNC is undervalued by 18.0% with a GF Value™ of $83.37, despite insider sales totaling $5.2 million over the past three months. The company's GF Score™ is 73/100, highlighting strong profitability and valuation but weaker growth.
BioMarin has announced that the FDA accepted its supplemental New Drug Application (sNDA) for VOXZOGO, targeting full approval for achondroplasia by February 28, 2027. This application is supported by extensive long-term safety and efficacy data from three ongoing studies, demonstrating significant improvements in skeletal growth for children. Full approval is expected to expand VOXZOGO's market reach, addressing global demand and enhancing BioMarin's revenue potential while solidifying its leadership in rare disease treatments.
Centene Corp. (ISIN US15133V1035) is a major US managed-care company focused on government-sponsored health plans like Medicaid and Medicare. The company's performance is heavily influenced by US healthcare policy, regulatory changes, and reimbursement trends, making these factors central to its long-term investment narrative. Centene's business model involves administering health benefits for various populations, with its success tied to effective medical cost management, disciplined underwriting, and strategic operational diversification.
Centene Corporation's subsidiary, Meridian Health Plan of Illinois, has secured a four-year renewal of its contract under the state's HealthChoice Illinois Medicaid program, effective from January 1, 2027, through 2030. This renewal, while not expected to significantly boost near-term earnings, is critical for maintaining premium revenues and enhancing long-term earnings visibility for Centene, given its reliance on government-sponsored healthcare programs. The company's shares have rallied 64.3% year-to-date, outperforming the industry, and its 2026 earnings are projected to grow by 66.4%.
Centene Corporation announced it will release its Q2FY26 financial results on Tuesday, July 28, 2026, at approximately 6:00 a.m. ET, followed by a conference call at 8:30 a.m. ET to discuss the results. Investors and interested parties can access the call via dial-in numbers or a live audio webcast through the company's website. Centene, a Fortune 500 healthcare enterprise, provides services to Medicaid, Medicare, and Health Insurance Marketplace members.
Centene Corp. is a major US managed care player, focusing on government-sponsored programs like Medicaid and ACA marketplaces, alongside specialty services. Its diversified model balances growth across these segments, requiring careful management of medical cost trends and regulatory compliance. The company's strategy emphasizes contract retention, expansion into new states, and efficient benefit design to ensure stable enrollment and predictable medical costs.
Barclays has reaffirmed its Hold rating on Agilon Health (AGL), setting a price target of $81.00. Analyst Andrew Mok CFA covers the Healthcare sector and has a 51.86% success rate. The broader analyst consensus for Agilon Health is also a Hold, with an average price target of $57.15, following the company's recent earnings report of $1.42 billion in quarterly revenue and a net profit of $29.97 million.
Old Republic International Corporation (NYSE: ORI) announced that it will release its second quarter 2026 financial results before the market opens on Thursday, July 23, 2026. The company will also host an earnings conference call at 3:00 p.m. Eastern time on the same day to discuss the results, which will be accessible via webcast and phone. Historically, earnings releases have often resulted in negative short-term stock movements, while call announcements have seen small positive reactions.
Centene Corporation's Illinois subsidiary, Meridian Health Plan of Illinois, Inc., has secured a four-year contract renewal to continue providing services for the HealthChoice Illinois Medicaid managed care program, starting January 1, 2027. The renewed contract highlights Meridian's strong local partnerships and commitment to delivering high-quality, coordinated care to approximately 2.4 million Medicaid-eligible residents. This news comes as Centene's stock has shown positive performance, trading near its 52-week high, and the company has received favorable analyst ratings and strategic board appointments.
Shares of Alignment Healthcare (NASDAQ:ALHC) dropped 16.7% after a former executive filed a whistleblower lawsuit, alleging the company misreported expenses to inflate profits. The suit claims that reclassifying certain expenses would turn a positive adjusted EBITDA for 2024 into a loss. Alignment Healthcare denies the allegations, stating an independent audit found no basis for the claims, and the company plans to vigorously defend itself.
Centene Corp, a major U.S. managed care company, is navigating ongoing shifts in government healthcare programs, particularly Medicaid and Medicare. Investors are closely monitoring how the company balances growth, reimbursement changes, and margin discipline in its core markets. Its financial performance is tied to member volume, the mix of enrollees, and medical cost trends, making margin management a key focus for its valuation.
Centene Corp. (CNC) shares rose 1.47% to $67.09 on Wednesday, outperforming the broader market, which saw the S&P 500 Index fall 0.28% and the Dow Jones Industrial Average fall 1.09%. This marks the company's second consecutive day of gains, despite an overall tough trading session.
UnitedHealth Group (UNH) is investing $1.5 billion in AI initiatives for 2026, aiming to integrate AI across all its operations, including insurance, pharmacy, and care delivery, to simplify healthcare processes and improve user experience. The company expects these investments to streamline prior authorizations, accelerate prescription approvals, and enhance clinical productivity, extending beyond mere cost savings to strengthen customer relationships and expand software revenue. While competitors like Humana and Centene also leverage AI for efficiency, UNH's comprehensive approach positions it to reinforce its competitive standing in the digital healthcare industry.
Centene Corp. continues to operate as a major U.S. managed care provider, offering Medicaid, Medicare, and marketplace plans. The company's revenue is largely derived from government-sponsored programs, with contract renewals influenced by quality metrics and cost management. Its presence in the Affordable Care Act marketplace is significant, attracting price-sensitive consumers, though profitability is subject to policy changes and regulatory requirements.
Centene Corp (CNC) currently exhibits a "Strong Buy" technical sentiment, based on an analysis of its moving averages and oscillators. The MACD indicator provides a Buy signal, and the stock is trading above its 60-day and 200-day moving averages. Key resistance is at $69.203 and support at $61.628, while the RSI suggests a neutral condition.
Centene Corp. will withdraw its participation in Arkansas' Medicaid expansion program (ARHOME) next year, affecting approximately one-third of the program's enrollees. The Department of Human Services will transfer these beneficiaries to other eligible plans, with no immediate action required by enrollees. This decision follows a drop in individual coverage enrollees through the Affordable Care Act and coincides with Arkansas implementing new Medicaid work requirements.
Health insurer Centene will cease its participation in Arkansas's Medicaid expansion program, ARHOME, beginning next year. This decision will affect approximately one-third of the program's 211,000 enrollees, who will be transferred to existing BlueCross Blue Shield plans. The withdrawal comes as Arkansas prepares to reinstate work requirements for Medicaid recipients starting in January.
Centene Corp., a major health insurer and parent company of three Arkansas health insurance plans, will cease participation in Arkansas's Medicaid expansion program, ARHOME, starting next year. This decision will impact about one-third of the more than 211,000 Arkansans currently enrolled in Centene plans (Ambetter, QCA Health Plan, and QualChoice Life and Health). The Department of Human Services (DHS) will transfer these enrollees to other eligible plans, with BlueCross BlueShield's three plans remaining in the program.
Centene Corp., the parent company of several Arkansas health insurance plans, will withdraw from the state's Medicaid expansion program (ARHOME) next year. This decision will impact about one-third of the over 211,000 Arkansans currently enrolled in Centene’s ARHOME plans, who will be transferred to other eligible plans. The state Department of Human Services will provide instructions to beneficiaries soon, while new work requirements for Medicaid recipients are set to be reinstated next year under the One Big Beautiful Bill Act.
Centene Corp., the parent company of several Arkansas health insurance plans, will withdraw from the state's Medicaid expansion program, ARHOME, starting next year. This decision will impact approximately one-third of the 211,000 Arkansans currently enrolled in Centene's three plans, who will be transferred to other eligible plans. The move comes as Arkansas prepares to reinstate work requirements for Medicaid recipients next year.
Cantor Fitzgerald maintained an "Overweight" rating for Centene Corporation (CNC) and raised its price target from $60.00 to $75.00, indicating increased confidence in the company. GuruFocus rates CNC as undervalued by 20.9% with a GF Value™ of $83.45 and a GF Score™ of 73/100, highlighting strong profitability and valuation. Despite this, insider activity shows $5.2 million in sales and a lower growth rank, suggesting investors should consider these factors.
UnitedHealth announced that an audit by FTI Consulting found nearly 97% of diagnoses made by its HouseCalls home-health unit in 2025 were supported by patient medical records. This comes after scrutiny from lawmakers and the Department of Health and Human Services regarding unsupported diagnoses impacting Medicare Advantage payments. The company acknowledges room for improvement in documentation practices.
Cantor Fitzgerald has increased its price target for Centene Corp. shares to $75 from $60, maintaining an Overweight rating, citing a favorable outlook for payors and continued strength in government insurance lines despite Medicaid concerns. Centene, trading at $66.05, is seen as undervalued by InvestingPro, with a Fair Value of $79.93. The firm highlighted Centene and UNH as top payor picks, with Centene set to report earnings on July 28th.
Cantor Fitzgerald has raised its price target for Centene Corp. (NYSE:CNC) shares to $75 from $60, maintaining an Overweight rating. This increase reflects a positive outlook on payors heading into the second quarter 2026 earnings season, despite concerns around Medicaid, with the firm noting encouraging commentary on value-based care. Centene, trading near
Centene Corp. is a major US managed care provider that focuses on government-sponsored healthcare programs like Medicaid, Medicare, and Affordable Care Act marketplaces. The company's business model involves coordinating care, managing medical costs, and providing access to healthcare networks for low-income and underserved populations. Centene's success is closely tied to policy decisions, regulatory changes, and efficient management of medical costs and membership dynamics, including Medicaid redeterminations.
Centene Corp., parent company of several Arkansas health insurance plans, will cease participation in the state's Medicaid expansion program, ARHOME, starting next year. This decision will affect approximately one-third of the more than 211,000 Arkansans currently enrolled in Centene's three plans, who will be transferred to other eligible plans. The change comes as Arkansas prepares to reinstate work requirements for Medicaid recipients under the One Big Beautiful Bill Act.
This July 2026 update details regulatory and legislative changes impacting several key areas. It covers developments in gender identity discrimination under the ACA, FLSA overtime exemption standards, the ERISA status of "Trump Accounts," and recent antitrust settlements for Blue Cross Blue Shield. The update also includes information on PCORI fee reporting, Massachusetts MCC standards for 2027, and mid-year increases in Paid Family and Medical Leave benefits in certain states.
Centene Corp., parent company of several Arkansas health insurance plans, will cease participation in the state's Medicaid expansion program, ARHOME, next year. This decision affects approximately one-third of the 211,000 Arkansans enrolled in ARHOME, who will be transferred to plans offered by BlueCross BlueShield. The change comes as Arkansas prepares to reinstate Medicaid work requirements under the One Big Beautiful Bill Act.
Centene Corp. will withdraw from Arkansas’ Medicaid expansion program, ARHOME, starting next year. This move will impact approximately one-third of the 211,000 Arkansans currently enrolled in Centene’s three plans. The Department of Human Services will transfer these enrollees to other eligible plans offered by BlueCross BlueShield.
Centene Corp., the parent company of several Arkansas health insurance plans, announced it will cease participation in the state's Medicaid expansion program, ARHOME, starting next year. This decision will impact about one-third of the 211,000 Arkansans currently enrolled in Centene's three plans, who will be transferred to other eligible plans. The move comes as Arkansas also prepares to reinstate Medicaid work requirements in 2027.
Centene Corp., the parent company of several Arkansas health insurance plans, will cease participation in the state's Medicaid expansion program, ARHOME, next year. This decision affects approximately one-third of the 211,000 Arkansans enrolled in ARHOME, who will be transferred to other eligible plans. The move comes as Arkansas prepares to reinstate Medicaid work requirements under the One Big Beautiful Bill Act.
Centene Corp. (CNC) shares fell by 2.67% to $66.05 on Monday, despite a generally favorable trading session for the broader stock market. The S&P 500 Index rose 0.72% and the Dow Jones Industrial Average gained 0.29%. This marked Centene's second consecutive day of losses.
Centene Corp., one of the two main providers of health insurance marketplace plans in Arkansas, announced its intention to withdraw from the state's Medicaid expansion program (ARHOME) starting in 2027. This move will affect approximately 70,000 Arkansans currently covered by Centene plans, who will be transitioned to other providers. Following Centene's departure, Arkansas Blue Cross and Blue Shield will be the sole participating company in the ARHOME program.
Centene Corp. plans to withdraw from Arkansas' ARHOME Medicaid expansion program in 2027 due to "funding challenges," leaving Arkansas Blue Cross and Blue Shield as the sole provider. Approximately 70,000 beneficiaries currently covered by Centene will be transitioned to other plans by the state. While exiting ARHOME, Centene will continue to offer Ambetter marketplace plans, Medicare, employer/group offerings, and participate in the PASSE program in Arkansas.
Centene Corp is re-evaluating its strategy and cost structure in response to the changing regulatory and reimbursement landscape within the US managed care sector. The company primarily focuses on government-sponsored health programs like Medicaid, Medicare, and Affordable Care Act marketplace plans, necessitating strict operational discipline and effective risk management. Centene's business model integrates health plan administration, provider network management, and care coordination to provide comprehensive health solutions.
Centene Corporation is enhancing its fraud prevention efforts through advanced analytics and AI-enabled tools to improve profitability in its government-sponsored healthcare businesses. This strategy, particularly effective in Medicaid, helped increase Q1 2026 adjusted EPS by 16.2% and improved the Medicaid health benefits ratio. These initiatives aim to strengthen cost controls and provide a competitive advantage, with competitors like UnitedHealth Group and Elevance Health also focusing on similar strategies.
Centene Corporation is enhancing its fraud prevention strategy by integrating advanced analytics and AI, aiming to improve profitability in its government-sponsored healthcare businesses. These efforts have already contributed to improved Medicaid margins and a raised adjusted EPS guidance for 2026. The company's focus on payment integrity and AI-driven analytics is expected to strengthen margin recovery and provide a competitive advantage, despite ongoing healthcare cost challenges.
Centene Corporation is enhancing its fraud, waste, and abuse prevention strategies, using advanced analytics and AI, to improve profitability in its government-sponsored healthcare businesses. These efforts have already contributed to improved Medicaid margins in Q1 2026, leading to raised EPS guidance for the year. Competitors like UnitedHealth Group and Elevance Health are also focusing on similar AI-driven payment integrity measures.
Ambetter health plans by Centene Corp. are a major product line on the Affordable Care Act (ACA) marketplaces, providing essential health benefits to millions of US families. The plans offer tiered options (bronze, silver, gold), digital tools, and focus on affordability for individuals and families without employer-sponsored coverage. Ambetter's presence across many states and its integration with ACA subsidies make it a significant player in the national health insurance landscape, affecting both consumers and Centene's financial performance.
Centene Corp. is a leading U.S. managed care company primarily serving Medicaid, Medicare, and Affordable Care Act marketplace members. The company emphasizes refining its portfolio and cost structure for sustainable growth within government-sponsored health programs, relying on operational efficiency and robust cost management strategies. Its business model is sensitive to U.S. healthcare policy and macroeconomic factors, which influence its membership and revenue, making ongoing adaptation crucial.
This article reviews the Q1 earnings for health insurance providers, highlighting Centene (NYSE:CNC) as a top performer. It discusses Centene's strong revenue and EPS beat, along with CVS Health's exceptional quarter. Conversely, Cencora (NYSE:COR) is noted for a weaker performance, while Clover Health (NASDAQ:CLOV) and Progyny (NASDAQ:PGNY) also showed strong results and growth.
Centene Corp. is a major player in the US managed care and government-sponsored health plan market, focusing on Medicaid, Medicare, and marketplace coverage. The company's financials are significantly influenced by membership growth, medical cost management, and policy changes. Centene uses care coordination, digital tools, and data analytics to optimize health outcomes and manage costs within its diverse health plans for individuals and employer groups.
Molina Healthcare specializes in government-sponsored health plans, primarily focusing on Medicaid, Medicare, and Affordable Care Act (ACA) marketplaces. The company operates as a managed care organization, contracting with state agencies to provide health benefits to vulnerable populations, emphasizing care coordination and cost control. Its business model, which includes a diversified portfolio of government-related health plans, is attractive to investors interested in publicly funded healthcare.
Centene Corp. is a major US managed care provider, focusing on government-sponsored healthcare programs like Medicaid and Medicare Advantage, serving millions of members. The company's business model revolves around coordinating and financing healthcare services for public entities, making its long-term prospects tied to government policies, demographic trends, and healthcare spending. Investors view Centene as an exposure to government-backed health programs, with its performance influenced by enrollment, cost control, and policy developments.
This article provides the latest SEC filing information and comprehensive financial data for Humana Inc. (HUM). It details various financial metrics such as market cap, income, sales, P/E ratios, dividend information, and performance indicators, alongside insider ownership and institutional transactions. The data reflects the company's financial health and stock performance as of July 2, 2024.
Centene's integrated healthcare model, combining government health plans with clinical, pharmacy, and community-based services, is expected to support its earnings growth. The company serves 26.3 million members, allowing for economies of scale, and is leveraging technology and data analytics to manage costs and improve outcomes. Despite regulatory challenges, Centene's investments in technology and clinical programs are set to drive margin recovery and sustainable long-term earnings growth.
Centene Corporation (CNC) is highlighted as a top momentum stock with a strong Relative Strength Index (RSI) of 67 and a high Quant rating of 4.94, despite historical trends suggesting July can be challenging for momentum stocks. The company, a significant player in the managed healthcare sector with a $33.75 billion market cap, has a GF Score™ of 74, indicating solid performance, particularly in profitability. However, investors are advised to exercise caution due to a low growth rank and significant insider selling, totaling $5.2 million over the past three months.
Centene Corporation's integrated healthcare model, combining government-sponsored health plans with coordinated clinical services, is supporting its earnings potential by effectively managing medical costs and improving health outcomes. The company is leveraging technology and data, including AI, to enhance operational capabilities and pricing decisions. Despite regulatory challenges, these efforts, along with its strong first-quarter 2026 performance and raised EPS guidance, position Centene for sustainable long-term growth, competing with giants like UnitedHealth and Elevance Health.
Molina Healthcare, a US-based managed care company, specializes in providing health insurance services through government programs like Medicaid and Medicare. The company's growth and profitability are closely tied to enrollment levels, effective management of medical costs relative to fixed payments, and the ever-changing policy environment surrounding public health coverage. Investors closely monitor these factors, along with regulatory developments and industry performance, to assess Molina Healthcare's financial health and future prospects.
This article from Investing.com announces the filing of a Form 4 for Centene Corp on July 1st. It also includes various financial market data such as indices, commodities, bonds, and stocks, along with trending news and market movers. The content primarily serves as a placeholder for a financial news update and features extensive financial data and news headlines.
